Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-0520 Gel for Prevention of Taxane-Induced Peripheral Neuropathy
NCT07082764Phase 2Not yet recruiting
- Sponsor
- Tarian Pharma
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brimonidine transdermal lotion in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Tarian Pharma. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
brimonidine transdermal lotion
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07082764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082764.